PRAMEF33

Across TCGA pan-cancer cohorts, PRAMEF33 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of PRAMEF33’s most consistent transcriptional readouts.

The strongest signal is observed in cholangiocarcinoma (CHOL), where PRAMEF33 RNA is repressed in tumor relative to normal tissue. In most cancer types PRAMEF33 is over-expressed in tumor, although a few such as CHOL show the opposite, repressed pattern.

CHOL and KIRC are the cancer types where PRAMEF33 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRAMEF33 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CHOL	All	All	−0.507	.013	1	view →
KIRC	All	All	+0.003	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

PRAMEF33–CHOL

Open the CHOL breakdown →